Background As known, rheumatoid arthritis (RA) is associated with accelerated atherosclerosis development. Traditional modifiable risk factors such as hypertension and endothelial dysfunction and its correcrion plays a significant role in RA pts.
Objectives We aimed to evaluate the effects of L-Arginine on endothelial function and blood pressure control in RA patients combined with hypertension.
Methods 42 patients (4 M, 38 F, mean age – 54,11±2,64 years) with RA combined with hypertension were enrolled. The average duration of RA was 8,05±0,69 years, the mean DAS28 - 2,74±0,16. 21 (50%) patients received the standard treatment and L-Arginine aspartate 30 ml/day during 4-6 weeks (study group), while 21 (50%) (control group) – received only the standard treatment based on ACE inhibitors. Blood pressure, endothelial-dependent flow mediated vasodilatation of brachial artery were measured in all patients at baseline and to the end of the study.
Results Endothelial-dependent flow mediated vasodilatation lesion was established in the majority of patients – 30 (71.43%), mean level 6.13±2.41%. After 4-6 weeks of treatment with L-Arginine mean endothelial-dependent flow mediated vasodilatation was 10,16±2.51% compared with standard therapy – 6.97±1.84% (p<0.05). Endothelial function had been normalized in 9 (43%) patients and increased by 46,36%. The level of mean blood pressure to the end of the study was significantly lower among patients of study group (128.4±3.5 vs 134.2±3.1, p<0.05).
Conclusions L-Arginine aspartate significantly improves endothelial function and has an additional hypotensive effect in rheumatoid arthritis patients with hypertension.
Disclosure of Interest None declared